Fosun Pharma：AKYNZEO®fosnetupitant/palonosetron concentrated solution for injectionapproved for marketing in China.
The concentrated solution for injection of fosnetupitant/palonosetron (AKYNZEO®, NEPA), a novel antiemetic combination drug for chemotherapy introduced by Fosun Pharma/Helsinn Group, covers two major areas: oncological supportive care and pain management supportive treatment, further enriching clinical treatment options in China.
The recently approved Fosnetupitant/Palonosetron Concentrated Solution for Injection (AKYNZEO®; NEPA) is a Category 5.1 imported novel combination drug developed in collaboration with the Helsinn Group. It is approved for the prevention of chemotherapy-induced nausea and vomiting (CINV), offering a new long-acting solution for CINV treatment in China.
This drug features an innovative dual-mechanism formulation, consisting of 235 mg fosnetupitant and 0.25 mg palonosetron. Fosnetupitant is a NK1 receptor antagonist, while palonosetron is a 5-HT3 receptor antagonist. The synergistic action of these two targets provides comprehensive coverage of both the acute and delayed phases of chemotherapy-induced vomiting, effectively improving the overall control rate of refractory CINV, while simplifying clinical combination regimens and enhancing treatment convenience.
As a well-established global innovative product, the drug was first approved in the United States in April 2018 for use in combination with dexamethasone for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic chemotherapy in adults. It subsequently received marketing authorization in the European Union in December 2021. Its clinical efficacy and safety have been validated across multiple regions worldwide.
Buy AKYNZEO®（fosnetupitant/palonosetron concentrated solution for injection） online from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.
